Patent Grant Strengthens Hoth's RNA Therapeutics Pipeline with Broad Claims Covering KIT-Targeted Antisense Oligomers for Oncology and Immunology Applications NEW YORK, April 17, 2025 /PRNewswire/ -- ...
HT-KIT demonstrates significant tumor downregulation and over 80% reduction in KIT expression in preclinical models of GIST and systemic mastocytosis. The therapy targets KIT gene expression at the ...
CRISPR gene editing has transitioned from a laboratory curiosity to a cornerstone of modern biotechnology, revolutionizing our approach to genetic diseases, including Charcot-Marie-Tooth (CMT) disease ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback